Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. A Meta-Analysis Comparing Different Oral Anticoagulation for the Treatment of Ventricular Thrombus.Reviews in cardiovascular medicine · 2022
   Pooled it
2. Stroke network performance during the first COVID-19 pandemic stage: A meta-analysis based on stroke network models.International journal of stroke : official journal of the International Stroke Society · 2021
   Pooled it
3. COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023
   Article
4. Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection.Journal of clinical medicine · 2023
   Article
5. A case series of myocardial infarction in SARS-CoV-2-infected patients: Same complication, different outcomes.Clinical case reports · 2022
   Article
6. Economy- and Social-Based Strategies for Anticoagulation of Patients with Atrial Fibrillation.Arquivos brasileiros de cardiologia · 2022
   Article
7. Thrombosis, an important piece in the COVID-19 puzzle: From pathophysiology to therapy.Anatolian journal of cardiology · 2021
   Review
8. Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: a role for direct anticoagulants?Journal of thrombosis and thrombolysis · 2021
   Article
9. [Impact of COVID-19 Pandemic on Medical Care of Patients with Inherited Bleeding Disorders].Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2021
   Article
10. COVID‑19 and ischemic stroke: Mechanisms of hypercoagulability (Review).International journal of molecular medicine · 2021
    Review
11. Light and shadows of the new therapies for haemophilia treatment in the COVID-19 era.Blood transfusion = Trasfusione del sangue · 2021
    Article
12. Pharmacotherapy of atrial fibrillation in COVID-19 patients.Cardiology journal · 2021
    Article
13. Confronting COVID-19: Issues in Hemophilia and Congenital Bleeding Disorders.Seminars in thrombosis and hemostasis · 2020
    Review
14. COVID-19 update: Covid-19-associated coagulopathy.Journal of thrombosis and thrombolysis · 2020
    Review
15. Therapeutic choices in persons with haemophilia at the time of COVID-19.Blood transfusion = Trasfusione del sangue · 2020
    Article
16. Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy.Cureus · 2020
    Review
17. Special Care Dentistry and COVID-19 Outbreak: What Lesson Should We Learn?Dentistry journal · 2020
    Article
18. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol.Drugs in context · 2020
    Article

Corrections and comments

• Commented on by
  DOACs and "newer" hemophilia therapies in COVID-19: Reply.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as